Treatment-subgroup interaction: An example from a published, phase II clinical trial

Contemporary Clinical Trials

Volumn 30, Issue 3, 2009, Pages 279-281

  Behrendt, Carolyn E ^a   Gehan, Edmund A ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Between patient heterogeneity; Phase II clinical trial; Treatment subgroup interaction

Indexed keywords

AMSACRINE; CYTARABINE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ACUTE LEUKEMIA; ADULT; ANALYSIS OF COVARIANCE; ANALYTICAL ERROR; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER SIMULATION; CONTROLLED STUDY; FALSE NEGATIVE RESULT; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PREDICTION; PROBABILITY; PROGNOSIS; STANDARD; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; AMSACRINE; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE II AS TOPIC; CYTARABINE; HUMANS; LEUKEMIA; PATIENT SELECTION; PREDNISONE; PROGNOSIS; RESEARCH DESIGN; TREATMENT OUTCOME; VINCRISTINE;

EID: 67349120551     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2009.02.002     Document Type: Article

References (10)

1. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1989) 1-10
2. Chen K., and Shan M. Optimal and minimax three-stage designs for phase II oncology clinical trials. Contemp Clin Trials 29 (2008) 32-41
3. Thall P.F., Simon R.M., and Estey E.H. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 14 (1995) 357-379
4. Thall P.F., and Wathen J.K. Bayesian designs to account for patient heterogeneity in phase II clinical trials. Curr Opin Oncol 20 (2008) 407-411
5. Wathen J.K., Thall P.F., Cook J.D., and Estey E.H. Accounting for patient heterogeneity in phase II clinical trials. Stat Med 27 (2008) 2802-2815
6. Keating M.J., Gehan E.A., Smith T.L., et al. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol 5 (1987) 710-721
7. Keating M.J., Smith T.L., Gehan E.A., et al. A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia. Cancer 50 (1982) 457-465
8. Smith T.L., Gehan E.A., Keating M.J., and Freireich E.J. Prediction of remission in adult acute leukemia: development and testing of predictive models. Cancer 50 (1982) 466-472
9. Hosmer Jr. D.W., and Lemeshow S. Applied Logistic Regression. 2nd edition (2000), John Wiley & Sons, Inc., New York
10. Gehan E.A. The evaluation of therapies: historical control studies. Stat Med 3 (1984) 315-324